Business Context and Reporting Period
Oaktree Acquisition Corp. III Life Sciences is a Cayman Islands exempted company and a blank check entity formed to effect a business combination with one or more life sciences businesses. The company is an emerging growth company and a shell company. As of the filing date, the company has not commenced operations or selected a specific business combination target. This report covers the quarter ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q4 2024 (Prior Period) |
|---|---|---|
| Net Income | $1,658,791 | Not provided in text |
| Operating Expenses | $444,802 | Not provided in text |
| Interest Income (Trust Account) | $2,103,593 | Not provided in text |
| Cash (Outside Trust) | $1,281,483 | $1,357,044 |
| Cash Held in Trust Account | $195,682,615 | $193,579,022 |
| Total Assets | $197,240,594 | $195,250,622 |
| Total Liabilities | $8,077,252 | $7,746,071 |
| Working Capital | $423,958 | Not provided in text |
| Net Cash Used in Operating Activities | ($75,561) | Not provided in text |
Material Changes and Financial Position
- Trust Account Growth: The Trust Account balance increased by approximately $2.1 million to $195.7 million, driven entirely by interest earned on U.S. government securities. The redemption value per share rose from $10.08 to $10.19.
- Profitability: The company reported a net income of $1.66 million, primarily due to interest income of $2.1 million offset by general and administrative expenses of $444,802.
- Liquidity: Cash held outside the Trust Account decreased by $75,561 to $1.28 million. The company maintains sufficient working capital to operate for at least one year from the filing date.
- Liabilities: Current liabilities increased to $1.06 million, largely due to a $480,833 increase in amounts "Due to related party" for administrative services.
Outlook, Risks, and Management Commentary
- Business Combination Deadline: The company must complete an initial business combination within 24 months of its IPO (October 2024), or by October 2026, or it will liquidate.
- Capital Structure: The company has 19,199,029 Class A shares subject to redemption and 4,799,758 Class B founder shares. There are 3,956,601 warrants outstanding exercisable at $11.50 per share.
- Deferred Fees: A deferred underwriting fee of $6.72 million and deferred legal fees of $299,088 are payable only upon the successful completion of a business combination.
- Risks: The filing highlights risks associated with geopolitical conflicts (Russia/Ukraine, Israel/Hamas), potential trade policy changes, and the inherent uncertainty of completing a business combination. The company has no operating history and generates no operating revenue.
- Related Party Transactions: The company pays its Sponsor $25,000 per month for administrative services. As of March 31, 2025, $75,000 in such fees was accrued.
Investor Verification Checklist
- Verify the current redemption value per share ($10.19) and the total Trust Account balance ($195.7M) against recent market data.
- Confirm the timeline for the mandatory liquidation date (24 months from IPO closing).
- Review the status of the Sponsor's indemnification obligations regarding third-party claims against the Trust Account.
- Monitor the company's cash burn rate outside the Trust Account to ensure sufficiency for the remaining search period.
- Check for any updates on the partial exercise of the over-allotment option and the forfeiture of remaining units.